Effective on May 11th, Gord Froehlich has retired from Kane Biotech as the Chief Executive Officer. Froehlich said, “It has been a privilege to work with a very dedicated and experienced team at Kane Biotech. It has also been a pleasure to work with the Directors of our Board who are engaged in the business and have offered me great support and guidance. I look forward to relaxing and seeing Kane Biotech’s business grow and I am confident that Mark and the team at Kane will continue to move our Company forward.”
Replacing Froehlich is Mark Ahrens-Townsend. Ahrens-Townsend stated, "I am honored and excited about the opportunity to lead Kane Biotech through its next phase. The Company has a strong history of technical innovations in biofilms that have significant opportunities in a variety of products, applications and industries. I look forward to working with Kane Biotech’s talented and dedicated employees and Board to help build profitable growth producing value for shareholders, customers, and employees alike."
Board Chairman, Philip Renaud said, “Mark brings executive expertise in the areas of strategy, planning, business development and corporate growth. The Board felt Mark’s experience and proven leadership capabilities were the right fit for Kane Biotech to commercialize its extensive inventory of intellectual property in biofilms. We welcome Mark and look forward to working with him and the entire Kane Biotech management team. We sincerely thank Gord for his service, hard work and significant contributions given to Kane Biotech over the years. We appreciate Gord’s leadership and the many important strategic initiatives he has driven for the Company."
